The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

被引:2
|
作者
Xu, Kangwei [1 ]
Li, Jing [2 ]
Lu, Xu [1 ]
Ge, Xiaoqin [2 ]
Wang, Kaiqin [1 ]
Wang, Jiahao [2 ]
Qiao, Zhizhong [1 ]
Quan, Yaru [1 ]
Li, Changgui [1 ]
机构
[1] Natl Inst Food & Drug Control, NHC Key Lab Res Qual & Standardizat Biotech Prod, NMPA Key Lab Qual Res & Evaluat Biol Prod, 2 Tiantan Xili, Beijing 100050, Peoples R China
[2] Sinovac Life Sci Co Ltd, Daxing Biomed Ind Base Zhongguancun Sci Pk, 21 Tianfu St, Beijing 100050, Peoples R China
基金
北京市自然科学基金;
关键词
SARS-CoV-2; inactivated vaccines; Delta; immunogenicity; adjuvants;
D O I
10.3390/vaccines12010060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these vaccines in mice was evaluated. The Delta + MF59-like vaccine group produced the highest levels of S- and RBD-binding antibodies and live Delta virus neutralization levels after one shot of immunization, while mice in the Delta + Alum vaccine group had the highest levels of these antibodies after two doses, and the Delta + MF59-like and Delta + Alum vaccine groups produced high levels of cross-neutralization antibodies against prototype, Beta, and Gamma strain SARS-CoV-2 viruses. There was no significant decrease in neutralizing antibody levels in any vaccine group during the observation period. CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines excited different antibody subtypes compared with unadjuvanted vaccines; the Delta + CpG vaccine group had a higher proportion of IgG2b antibodies, indicating bias towards Th1 immunity. The proportions of IgG1 and IgG2b in the Delta + MF59-like vaccine group were similar to those of the unadjuvanted vaccine. However, the Delta + Alum vaccine group had a higher proportion of IgG1 antibodies, indicating bias towards Th2 immunity. Antigen-specific cytokine secretion CD4/8+ T cells were analyzed. In conclusion, the results of this study show differences in the immune efficacy of CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines in mice, which have significant implications for the selection strategy for vaccine adjuvants.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone
    Cheng, Chongsheng
    Wang, Yani
    Hu, Danjing
    Zhou, Wangji
    Liu, Chunlong
    Tian, Xinlun
    Zhang, Hongbing
    Xu, Ying-Chun
    Xu, Kai-Feng
    SCIENCE CHINA-LIFE SCIENCES, 2022, 65 (10) : 2118 - 2120
  • [42] Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone
    Chongsheng Cheng
    Yani Wang
    Danjing Hu
    Wangji Zhou
    Chunlong Liu
    Xinlun Tian
    Hongbing Zhang
    Ying-Chun Xu
    Kai-Feng Xu
    ScienceChina(LifeSciences), 2022, 65 (10) : 2118 - 2120
  • [43] SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
    Thiruvengadamt, Ramachandra
    Binayket, Akshay
    Awasthi, Amit
    LANCET INFECTIOUS DISEASES, 2022, 22 (03): : 301 - 302
  • [44] Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance
    Islam, Nazmul
    Griffin, Daniel O.
    Jarvis, Megan S.
    Cohen, Kenneth
    HELIYON, 2023, 9 (05)
  • [45] The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC-MS
    Xu, Kangwei
    Sun, Huang
    Wang, Kaiqin
    Quan, Yaru
    Qiao, Zhizhong
    Hu, Yaling
    Li, Changgui
    VACCINES, 2023, 11 (05)
  • [46] The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
    Sadun, Rebecca
    Crair, Dan
    Walter, Emmanuel B.
    Rogers, Jennifer
    Clowse, Megan
    Eudy, Amanda
    Sun, Kai
    Doss, Jayanth
    Criscione-Schreiber, Lisa
    Valencia, Sarah
    Moody, M. Anthony
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 408 - 410
  • [47] Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice
    Luan, Ning
    Cao, Han
    Wang, Yunfei
    Lin, Kangyang
    Hu, Jingping
    Liu, Cunbao
    VIRUSES-BASEL, 2023, 15 (06):
  • [48] Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy
    Bowes, Cynthia L.
    Naranbhai, Vivek
    St Denis, Kerri J.
    Lam, Evan C.
    Bertaux, Brittany
    Keane, Florence K.
    Khandekar, Melin J.
    Balazs, Alejandro B.
    Iafrate, John A.
    Gainor, Justin F.
    Willers, Henning
    RADIOTHERAPY AND ONCOLOGY, 2022, 166 : 88 - 91
  • [49] Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer
    Samdaengpan, Chayanee
    Sungkasubun, Prakongboon
    Chaiwiriyawong, Worawit
    Supavavej, Archara
    Siripaibun, Jomtana
    Phanthunane, Chumut
    Tantiyavarong, Walaipan
    Lamlertthon, Wisut
    Ungtrakul, Teerapat
    Tawinprai, Kriangkrai
    Soonklang, Kamonwan
    Thongchai, Thitapha
    Limpawittayakul, Piyarat
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [50] Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein
    Lim, Heeji
    Kim, Se Eun
    Lee, Yun Ha
    Hwang, Yun-Ho
    Kim, Su Hwan
    Kim, Mi Young
    Chung, Gyung Tae
    Kim, You-Jin
    Kim, Dokeun
    Lee, Jung-Ah
    VIROLOGY, 2022, 573 : 118 - 123